Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME)

Summary

The primary objective is to demonstrate the non-inferiority of bevacizumab to ranibizumab in the treatment of patients with DME (OCT central area thickness \> 275 μm) as determined by the change in best-corrected visual acuity (BCVA) in the study eye from baseline to month 6.

Timeline

Start

2012-06

Primary completion

2016-06

Completion

—

Publications

• Fickweiler W, Klaassen I, Vogels IM, Hooymans JM, Wolffenbuttel BH, Los LI, Schlingemann RO; BRDME Research Group. Association of Circulating Markers With Outcome Parameters in the Bevacizumab and Ranibizumab in Diabetic Macular Edema Trial. Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6234-6241. doi: 10.1167/iovs.16-20157.

Drugs

Indications